New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates
Peptide-based vaccines have demonstrated to be an important way to induce long-lived immune responses and, therefore, a promising strategy in the rational of vaccine development. As to malaria, among the classic vaccine targets, the Apical membrane antigen (AMA-1) was proven to have important B cell...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562794/?tool=EBI |
| _version_ | 1818433385511518208 |
|---|---|
| author | Raianna F. Fantin Vanessa G. Fraga Camila A. Lopes Isabella C. de Azevedo João L. Reis-Cunha Dhelio B. Pereira Francisco P. Lobo Marcela M. de Oliveira Anderson C. dos Santos Daniela C. Bartholomeu Ricardo T. Fujiwara Lilian L. Bueno |
| author_facet | Raianna F. Fantin Vanessa G. Fraga Camila A. Lopes Isabella C. de Azevedo João L. Reis-Cunha Dhelio B. Pereira Francisco P. Lobo Marcela M. de Oliveira Anderson C. dos Santos Daniela C. Bartholomeu Ricardo T. Fujiwara Lilian L. Bueno |
| author_sort | Raianna F. Fantin |
| collection | DOAJ |
| description | Peptide-based vaccines have demonstrated to be an important way to induce long-lived immune responses and, therefore, a promising strategy in the rational of vaccine development. As to malaria, among the classic vaccine targets, the Apical membrane antigen (AMA-1) was proven to have important B cell epitopes that can induce specific immune response and, hence, became key players for a vaccine approach. The peptides selection was carried out using a bioinformatic approach based on Hidden Markov Models profiles of known antigens and propensity scale methods based on hydrophilicity and secondary structure prediction. The antigenicity of the selected B-cell peptides was assessed by multiple serological assays using sera from acute P.vivax infected subjects. The synthetic peptides were recognized by 45.5%, 48.7% and 32.2% of infected subjects for peptides I, II and III respectively. Moreover, when synthetized together (tripeptide), the reactivity increases up to 62%, which is comparable to the reactivity found against the whole protein PvAMA-1 (57%). Furthermore, IgG reactivity against the tripeptide after depletion was reduced by 42%, indicating that these epitopes may be responsible for a considerable part of the protein immunogenicity. These results represent an excellent perspective regarding future chimeric vaccine constructions that may come to contemplate several targets with the potential to generate the robust and protective immune response that a vivax malaria vaccine needs to succeed. |
| first_indexed | 2024-12-14T16:20:15Z |
| format | Article |
| id | doaj.art-9e72fb7ec21843dbbeba50db95873202 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T16:20:15Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9e72fb7ec21843dbbeba50db958732022022-12-21T22:54:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-011611New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidatesRaianna F. FantinVanessa G. FragaCamila A. LopesIsabella C. de AzevedoJoão L. Reis-CunhaDhelio B. PereiraFrancisco P. LoboMarcela M. de OliveiraAnderson C. dos SantosDaniela C. BartholomeuRicardo T. FujiwaraLilian L. BuenoPeptide-based vaccines have demonstrated to be an important way to induce long-lived immune responses and, therefore, a promising strategy in the rational of vaccine development. As to malaria, among the classic vaccine targets, the Apical membrane antigen (AMA-1) was proven to have important B cell epitopes that can induce specific immune response and, hence, became key players for a vaccine approach. The peptides selection was carried out using a bioinformatic approach based on Hidden Markov Models profiles of known antigens and propensity scale methods based on hydrophilicity and secondary structure prediction. The antigenicity of the selected B-cell peptides was assessed by multiple serological assays using sera from acute P.vivax infected subjects. The synthetic peptides were recognized by 45.5%, 48.7% and 32.2% of infected subjects for peptides I, II and III respectively. Moreover, when synthetized together (tripeptide), the reactivity increases up to 62%, which is comparable to the reactivity found against the whole protein PvAMA-1 (57%). Furthermore, IgG reactivity against the tripeptide after depletion was reduced by 42%, indicating that these epitopes may be responsible for a considerable part of the protein immunogenicity. These results represent an excellent perspective regarding future chimeric vaccine constructions that may come to contemplate several targets with the potential to generate the robust and protective immune response that a vivax malaria vaccine needs to succeed.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562794/?tool=EBI |
| spellingShingle | Raianna F. Fantin Vanessa G. Fraga Camila A. Lopes Isabella C. de Azevedo João L. Reis-Cunha Dhelio B. Pereira Francisco P. Lobo Marcela M. de Oliveira Anderson C. dos Santos Daniela C. Bartholomeu Ricardo T. Fujiwara Lilian L. Bueno New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates PLoS ONE |
| title | New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates |
| title_full | New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates |
| title_fullStr | New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates |
| title_full_unstemmed | New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates |
| title_short | New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates |
| title_sort | new highly antigenic linear b cell epitope peptides from pvama 1 as potential vaccine candidates |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562794/?tool=EBI |
| work_keys_str_mv | AT raiannaffantin newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT vanessagfraga newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT camilaalopes newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT isabellacdeazevedo newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT joaolreiscunha newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT dheliobpereira newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT franciscoplobo newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT marcelamdeoliveira newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT andersoncdossantos newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT danielacbartholomeu newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT ricardotfujiwara newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates AT lilianlbueno newhighlyantigeniclinearbcellepitopepeptidesfrompvama1aspotentialvaccinecandidates |